Next Article in Journal
Increasing Egg Consumption at Breakfast Is Associated with Increased Usual Nutrient Intakes: A Modeling Analysis Using NHANES and the USDA Child and Adult Care Food Program School Breakfast Guidelines
Next Article in Special Issue
Dietary Management in Pediatric Patients with Crohn’s Disease
Previous Article in Journal
Unveiling the Correlation between Inadequate Energy/Macronutrient Intake and Clinical Alterations in Volunteers at Risk of Metabolic Syndrome by a Predictive Model
Previous Article in Special Issue
Diet Advice for Crohn’s Disease: FODMAP and Beyond
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 13
Issue 4
10.3390/nu13041378
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together

by
Francesco Palmese
1,
Rossella Del Toro
1,2,
Giulia Di Marzio
3,
Pierluigi Cataleta
1,
Maria Giulia Sama
1 and
Marco Domenicali
1,4,*
1
Department of Internal Medicine, AUSL della Romagna, S. Maria delle Croci Hospital, 48121 Ravenna, Italy
2
Endocrinology and Diabetes Unit, Campus Bio-Medico University of Rome, 00128 Rome, Italy
3
Department of Experimental and Clinical Medicine, University of Florence, Careggi University Hospital, 50139 Florence, Italy
4
Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, 40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
Nutrients 2021, 13(4), 1378; https://doi.org/10.3390/nu13041378
Submission received: 31 March 2021 / Revised: 16 April 2021 / Accepted: 17 April 2021 / Published: 20 April 2021
(This article belongs to the Special Issue Nutritional Intake in Patients with Crohn’s Disease)
Browse Figures
Versions Notes

Abstract

Sarcopenia is a prevalent condition in patients with Crohn’s disease (CD), representing an independent predictor factor for the development of major postoperative complications. Thus, a proper assessment of the muscle strength, by using different validated tools, should be deemed an important step of the clinical management of these patients. Patients with CD are frequently malnourished, presenting a high prevalence of different macro- and micro-nutrient deficiencies, including that of vitamin D. The available published studies indicate that vitamin D is involved in the regulation of proliferation, differentiation, and regeneration of muscle cells. The relationship between vitamin D deficiency and sarcopenia has been extensively studied in other populations, with interesting evidence in regards to a potential role of vitamin D supplementation as a means to prevent and treat sarcopenia. The aim of this review was to find studies that linked together these pathological conditions.

1. Introduction

Crohn’s disease (CD) is a chronic and progressive inflammatory bowel disease (IBD) that has a high impact on a patient’s quality of life. It is well known that all segments of the gastrointestinal tract can be affected by CD, mainly the terminal ileum and colon. Inflammation is generally segmental, asymmetrical, and transmural [1]. Although progress has been made to achieve prolonged remission, almost half of the patients over time will develop complications (i.e., strictures, fistulas, and abscesses) that require surgical treatments [2]. The pathogenesis of CD is not yet fully understood, however, it clearly involves multiple factors, i.e., genetic susceptibility, environmental factors, and intestinal microflora, resulting in dysregulation of multiple and overlapping immune pathways [1].
In the last decades, the prevalence of CD has increased continuously worldwide, especially in the developed countries, primarily due to environmental factors, such as changes in dietary patterns and alterations in body composition [1]. Among these, the loss of muscle mass resulting in a decrease of muscle strength, a condition named sarcopenia, is an increasingly prevalent condition in patients with CD and is a strong independent predictor factor for the appearance of major postoperative complications [3].
Nowadays, it is widely acknowledged that vitamin D is one of the factors involved in the proliferation, differentiation, and regeneration of muscle cells [4]. As proof of this, alterations in vitamin D levels seem to be related to sarcopenia prevalence in several pathological conditions, including CD [5,6].

2. Sarcopenia and Crohn’s Disease

2.1. Definition of Sarcopenia

In the last decades, there has been a widespread interest in research about sarcopenia, whereby now it is formally recognized as a disease with an ICD-10-MC diagnosis code [7]. According to the latest definition provided by the European Working Group On Sarcopenia In Older People 2 (EWGSOP-2), sarcopenia has been defined as a progressive and generalized skeletal muscle disorder, associated with an increased probability of adverse outcomes, among which falls fractures, physical disability, and mortality [8].
This definition has evolved during the last years, with the addition of the muscle strength to the former definition based only on the muscle mass [9]. Indeed, according to the current knowledge, muscle strength seems to be a more reliable parameter to predict the adverse outcomes mentioned above [10,11]. Moreover, alterations in muscle strength seem to be related not only to changes in muscle quantity but also to deep alterations in muscle quality, caused by modifications in the architecture and composition of muscle cells [8]. According to this evidence, the latest guidelines raise muscle strength as the primary parameter to be evaluated for detecting sarcopenia [8].

2.2. The Assessment of Sarcopenia

Due to the well-established negative impact of sarcopenia on several pathological conditions, it should be mandatory for every clinician in charge of patients affected by chronic diseases, to evaluate and exclude the presence of sarcopenia, by means of validated case-finding tools.
Among these, the SARC-F questionnaire is the most used in daily clinical practice for patients aged ≥ 65 [12]. It is a self-reported questionnaire, with low sensitivity but high specificity, based on the patient’s self-evaluation of five motor abilities, i.e., walking, rising from a chair, climbing stairs, carrying weights, and avoiding falls [12]. An alternative recommended case-finding tool is the Ishii screening test, which relates age, handgrip strength, and calf circumference [13]. Nevertheless, including a skeletal muscle strength evaluation could be considered a more reliable tool to detect sarcopenia.
Should the screening tests return positive, evidence of low muscle quantity or low muscle quality by the use of tools available to this purpose would confirm a formal diagnosis of sarcopenia. In clinical practice, tool selection may depend on several variables related to both the patient and healthcare setting [8]. A brief overview of these tools is presented in Table 1.

2.3. Sarcopenia in Patients with CD

In the last decade, sarcopenia has emerged as a primary factor in the nutritional assessment of patients affected by chronic inflammatory diseases, including IBD [14,15]. In fact, there is evidence indicating that this syndrome impacts the course of the disease, the responsiveness to specific therapies, and the outcomes of surgery [14].
Sarcopenia turns out to be a widespread condition in patients with IBD, in particular CD [16]. In a recent systematic review, it is reported that up to 60% of patients with IBD present a depletion of the muscle mass when compared with healthy subjects [16].
It is reported that patients with CD, affected by sarcopenia, result to be overweight or obese (a condition named “sarcopenic obesity”), rather than undernourished, at the nutritional assessment tests [17]. This extreme variability emphasizes the need for malnutrition and sarcopenia screening in all CD patients.
In addition to malabsorption and gastrointestinal surgery, other factors may contribute to the development of sarcopenia in patients with CD, such as eventual glucocorticoid treatment and hypogonadism, and a reduced physical activity [18,19,20]. It should be noted that the activation of inflammatory cytokines may contribute significantly to converting the muscle protein metabolism from synthesis to degradation, as shown in Figure 1 [18,21].
To investigate the connection between sarcopenia and CD, we performed a systematic review, according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist [22], based on the following Medical Subject Heading (MeSH) keywords: “Crohn’s disease”, “inflammatory bowel disease”, “sarcopenia”. The search, performed on 10 March 2021, was made on the following on-line databases: Scopus (www.scopus.com) (1969–2020), MEDLINE (www.nlm.nih.gov) (1969–2020), and the US National Library of Medicine (www.PubMed.gov). Two authors (F.P. and R.D.T.) performed the screening of titles and abstracts. Full-length versions of selected articles were then assessed for inclusion criteria: studies in patients aged >18 years; diagnosis of CD performed according to the current international guidelines; papers published in English; studies on IBD in which data on CD were clearly defined; studies in which the prevalence of sarcopenia was clearly quantified. The study selection process is presented in Figure 2. The following data were collected: number of patients; variable, test, and tool used to assess sarcopenia in patients with CD; percentage of patients with sarcopenia (Table 2).
It has to be underlined that not all the above-cited studies were primarily focusing on the assessment of sarcopenia in patients with CD, which was instead part of a more extensive analysis. A common finding emerging from these studies, which were performed in different areas of the world, is the high prevalence of sarcopenia in patients with CD. The cohorts of these studies were heterogeneous and the percentage of patients with sarcopenia ranged from 19% to 61.4%, among different study populations. However, when considering only the data from the studies which used the gold standard tools (CT and MRI), the prevalence of sarcopenia increases significantly, ranging from 31% to 61.4%. Lastly, no significant difference in sample size, between studies using more expensive and time-consuming techniques (CT and MRI) and those that used more affordable tools (BIA and Dyn), is noteworthy.
Despite these described data, in daily clinical practice, the assessment of sarcopenia is still considered a marginal issue. Indeed, the most recent guidelines on CD do not mention the term “sarcopenia” [35].

3. Vitamin D Deficiency and Crohn’s Disease

3.1. Definition of Vitamin D Deficiency

Vitamin D is known to be produced in the skin from sunlight exposure or derived from foods that naturally contain vitamin D. According to the Endocrine Society guidelines, Vitamin D deficiency is defined as a serum 25-hydroxyvitamin D (25(OH)D) below 20 ng/mL (50 nmol/L), and vitamin D insufficiency as a serum 25(OH)D of 21–29 ng/mL (525–725 nmol/L) [36]. However, among scientific societies worldwide there is no general agreement on normal serum levels of 25(OH)D. Screening for vitamin D deficiency is indicated for all patients considered at risk, while population screening is not recommended [37]. In clinical practice, the most used way to evaluate vitamin D status is to determine serum concentrations of circulating 25(OH)D, measured with a reliable assay [36].
Vitamin D deficiency is acknowledged as a global health issue [38]. In addition to playing a crucial role in calcium and phosphorus homeostasis to preserve bone health, several studies have demonstrated a pleiotropic effect in different physiological processes. In particular, it has been recognized as a regulator of the innate immune system, of cardiovascular and renal functions, of cancer progression [37], and is also involved in different acute and chronic diseases [39].

3.2. Prevalence of Vitamin D Deficiency in Patients with CD

In the last decades, several studies have established the presence of vitamin D deficiency in patients with IBD, suggesting its potential role in the pathogenesis of these autoimmune diseases.
As previously done for sarcopenia, we performed a systematic review to highlight the evidence that linked vitamin D deficiency to CD. The research was carried out according to the PRISMA checklist [22], on the online databases mentioned above and based on the following MeSH keywords: “Crohn’s disease”, “inflammatory bowel disease”, “vitamin D”, “cholecalciferol”, “25-hydroxyvitamin D”, “vitamin D deficiency”, “vitamin D status”. The analysis of the studies was performed by R.D.T. and F.P. The inclusion criteria were: studies in patients aged >18 years; diagnosis of CD performed according to the current international guidelines; diagnosis of vitamin D insufficiency or deficiency established for serum levels lower than 30 ng/mL; studies on IBD in which data on CD were clearly defined; studies in which the prevalence of vitamin D was clearly quantified; papers published in English. The following data were collected: number of patients; cut-off of 25(OH)D expressed in ng/mL adopted by the authors to define vitamin D deficiency; percentage of patients with vitamin D deficiency (Table 3). The study selection process is presented in Figure 3.
As shown in Table 3, all studies demonstrated vitamin D deficiency in patients with CD, ranging from 10.5% [49,59] to 100% [64], the majority showing high prevalence values.
It must be acknowledged that the majority of the studies in which vitamin D status was assessed were conducted on patients with IBD. To perform our review, we selected the studies in which the percentage of CD patients was clearly defined. 25(OH)D serum levels were expressed in ng/mL.
It should be specified that some authors provided different percentages based on the seasonal variability, with a lower prevalence of vitamin D deficiency occurring in summer than in winter [41,57,65,66], as expected.
Furthermore, recent data suggest that free 25(OH)D concentrations may be a better indicator than total 25(OH)D for the assessment of vitamin D status in patients with CD, due to the regulatory effects of glucocorticoid therapy and cytokines on vitamin D binding protein (VDBP) synthesis [70].

4. Vitamin D and Sarcopenia

4.1. Effects of Vitamin D on Skeletal Muscle Function

Over recent years, the potential role of vitamin D on muscle function and strength has been widely debated [4].
At a cellular level, it is known that vitamin D acts through both genomic and non-genomic pathways, as summarized in Figure 4. At the nuclear level, vitamin D can regulate gene expression by interacting with Vitamin D Receptor (VDR), thus forming a heterodimeric complex of liganded VDR with Retinoid-X-receptor (RXR) and up-regulating or down-regulating target genes transcription. The non-genomic effects of Vitamin D are mediated by the activation of intracellular signal pathways through signal molecules, e.g., phospholipase C and phospholipase A2, and the production of second messengers, protein kinases, and the opening of Ca2+ and Cl− channels as depicted in Figure 4.
Focusing on the biological mechanisms that regulate differentiation, proliferation, and regeneration of muscle cells, it has been demonstrated that vitamin D regulates several myogenic transcription factors involved in muscle cells proliferation, e.g., insulin-like growth factor 2 and follistatin [71], and in muscle cells differentiation, e.g., fetal myosin, the neural cell adhesion molecule, insulin-like growth factor 1, fibroblast growth factor and myogenic differentiation protein 1 [72,73].
Regarding muscle regeneration, it has been demonstrated that vitamin D promotes the initial increase of the cross-sectional area of skeletal muscle fibers, by arresting the cell cycle, and suppresses the expression of myostatin, a key factor implicated in muscular degeneration [74].
According to the current knowledge, vitamin D seems to mainly affect type IIA muscle cells, i.e., the “fast twitch oxidative” cells [71]. Indeed, by using muscle biopsy, in previous works it has been shown that vitamin D deficiency is associated with type IIA muscle cells atrophy and fibrosis [75] and, by contrast, the supplementation of vitamin D has been shown to increase the number and the diameter of type IIA muscle cells, thus increasing muscle strength [76].
Furthermore, it should be mentioned that elevated PTH may contribute to the pathogenesis of sarcopenia, given its direct effect on skeletal muscle protein metabolism and the recent demonstration that elevated PTH levels are associated with vitamin D deficiency in sarcopenia [77].

4.2. Vitamin D and Sarcopenia: Evidence from Other Patients

The relationship between vitamin D deficiency and sarcopenia has been extensively studied in other populations, and results from studies in these populations are interesting in regards to the potential role of vitamin D supplementation for the prevention and treatment of sarcopenia.
In particular, in the geriatric population, known to be at a high prevalence of vitamin D deficiency worldwide [78], a relationship between vitamin D and neuromuscular performance has been established [71,79].
Although the effects of the vitamin D on the intracellular nuclear and non-nuclear receptors to stimulate the growth and function of skeletal muscle cells has been well demonstrated in several studies, the clinical usefulness of oral vitamin D supplementation as a therapeutic mean to treat or prevent sarcopenia in older patients is still controversial [74].
This could interestingly be related to a decline in the VDR number with advancing age [80,81], thus making vitamin D supplementation probably more effective in younger patients.
It is worth noting that this specific issue has been the subject of a recent review within this journal and therefore will not be extensively discussed here [74].

5. The Missing Step: The Effect of Vitamin D Supplementation on Sarcopenia in Patients with CD

Our research aimed at finding relevant information in the scientific literature on the relationship between vitamin D supplementation and sarcopenia in patients with CD. However, in spite of the high prevalence of sarcopenia in patients with CD and the correlation between vitamin D metabolism and muscular performance, studies correlating these three clinical conditions are missing, although there is growing attention on this topic, especially among pediatric patients [82].
To the best of our knowledge, only Hradsky et al. performed a study on this issue, observing an improvement in muscle parameters after vitamin D supplementation in children with IBD, but without discrimination between CD and Ulcerative Colitis and using muscle strength as a variable to assess sarcopenia [83].
Given the role of vitamin D on muscle metabolism on a molecular basis, an improvement in sarcopenia in patients with CD could be expected with vitamin D supplementation. This open question requires further and appropriate studies.

Author Contributions

Conceptualization F.P., R.D.T. and M.D.; data collection, data analysis, manuscript preparation F.P., R.D.T. and G.D.M.; critical review, all authors. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Statement excluded.

Acknowledgments

The authors would like to thank Alexandra Boini for her helpful grammar revision of the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Torres, J.; Mehandru, S.; Colombel, J.F.; Peyrin-Biroulet, L. Crohn’s disease. Lancet 2017, 389, 1741–1755. [Google Scholar] [CrossRef]
  2. Peyrin-Biroulet, L.; Loftus, E.V.; Colombel, J.F.; Sandborn, W.J. The natural history of adult crohn’s disease in population-based cohorts. Am. J. Gastroenterol. 2010, 105, 289–297. [Google Scholar] [CrossRef] [PubMed]
  3. Grillot, J.; D’Engremont, C.; Parmentier, A.L.; Lakkis, Z.; Piton, G.; Cazaux, D.; Gay, C.; De Billy, M.; Koch, S.; Borot, S.; et al. Sarcopenia and visceral obesity assessed by computed tomography are associated with adverse outcomes in patients with Crohn’s disease. Clin. Nutr. 2020, 39, 3024–3030. [Google Scholar] [CrossRef] [PubMed]
  4. Bischoff-Ferrari, H.A. Relevance of vitamin D in muscle health. Rev. Endocr. Metab. Disord. 2012, 13, 71–77. [Google Scholar] [CrossRef]
  5. Mager, D.R.; Carroll, M.W.; Wine, E.; Siminoski, K.; MacDonald, K.; Kluthe, C.L.; Medvedev, P.; Chen, M.; Wu, J.; Turner, J.M.; et al. Vitamin D status and risk for sarcopenia in youth with inflammatory bowel diseases. Eur. J. Clin. Nutr. 2018, 72, 623–626. [Google Scholar] [CrossRef] [PubMed]
  6. Almurdhi, M.M.; Reeves, N.D.; Bowling, F.L.; Boulton, A.J.M.; Jeziorska, M.; Malik, R.A. Distal lower limb strength is reduced in subjects with impaired glucose tolerance and is related to elevated intramuscular fat level and vitamin D deficiency. Diabet. Med. 2017, 34, 356–363. [Google Scholar] [CrossRef]
  7. Vellas, B.; Fielding, R.A.; Bens, C.; Bernabei, R.; Cawthon, P.M.; Cederholm, T.; Cruz-Jentoft, A.J.; Del Signore, S.; Donahue, S.; Morley, J.; et al. Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force. J. Frailty Aging 2018, 7, 2–9. [Google Scholar]
  8. Cruz-Jentoft, A.J.; Bahat, G.; Bauer, J.; Boirie, Y.; Bruyère, O.; Cederholm, T.; Cooper, C.; Landi, F.; Rolland, Y.; Sayer, A.A.; et al. Sarcopenia: Revised European consensus on definition and diagnosis. Age Ageing 2019, 48, 16–31. [Google Scholar] [CrossRef]
  9. Cruz-Jentoft, A.J.; Baeyens, J.P.; Bauer, J.M.; Boirie, Y.; Cederholm, T.; Landi, F.; Martin, F.C.; Michel, J.P.; Rolland, Y.; Schneider, S.M.; et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing 2010, 39, 412–423. [Google Scholar] [CrossRef] [PubMed]
  10. Ibrahim, K.; May, C.; Patel, H.P.; Baxter, M.; Sayer, A.A.; Roberts, H. A feasibility study of implementing grip strength measurement into routine hospital practice (GRImP): Study protocol. Pilot Feasibility Stud. 2016, 2, 27. [Google Scholar] [CrossRef] [PubMed]
  11. Leong, D.P.; Teo, K.K.; Rangarajan, S.; Lopez-Jaramillo, P.; Avezum, A.; Orlandini, A.; Seron, P.; Ahmed, S.H.; Rosengren, A.; Kelishadi, R.; et al. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study. Lancet 2015, 386, 266–273. [Google Scholar] [CrossRef]
  12. Dent, E.; Morley, J.E.; Cruz-Jentoft, A.J.; Arai, H.; Kritchevsky, S.B.; Guralnik, J.; Bauer, J.M.; Pahor, M.; Clark, B.C.; Cesari, M.; et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J. Nutr. Health Aging 2018, 22, 1148–1161. [Google Scholar] [CrossRef] [PubMed]
  13. Locquet, M.; Beaudart, C.; Reginster, J.Y.; Petermans, J.; Bruyère, O. Comparison of the performance of five screening methods for sarcopenia. Clin. Epidemiol. 2018, 10, 71–82. [Google Scholar] [CrossRef]
  14. Balestrieri, P.; Ribolsi, M.; Guarino, M.P.L.; Emerenziani, S.; Altomare, A.; Cicala, M. Nutritional aspects in inflammatory bowel diseases. Nutrients 2020, 12, 372. [Google Scholar] [CrossRef]
  15. Plauth, M.; Bernal, W.; Dasarathy, S.; Merli, M.; Plank, L.D.; Schütz, T.; Bischoff, S.C. ESPEN guideline on clinical nutrition in liver disease. Clin. Nutr. 2019, 38, 485–521. [Google Scholar] [CrossRef]
  16. Ryan, E.; McNicholas, D.; Creavin, B.; Kelly, M.E.; Walsh, T.; Beddy, D. Sarcopenia and inflammatory bowel disease: A systematic review. Inflamm. Bowel Dis. 2019, 25, 67–73. [Google Scholar] [CrossRef]
  17. Adams, D.W.; Gurwara, S.; Silver, H.J.; Horst, S.N.; Beaulieu, D.B.; Schwartz, D.A.; Seidner, D.L. Sarcopenia Is Common in Overweight Patients with Inflammatory Bowel Disease and May Predict Need for Surgery. Inflamm. Bowel Dis. 2017, 23, 1182–1186. [Google Scholar] [CrossRef]
  18. Dhaliwal, A.; Quinlan, J.I.; Overthrow, K.; Greig, C.; Lord, J.M.; Armstrong, M.J.; Cooper, S.C. Sarcopenia in inflammatory bowel disease: A narrative overview. Nutrients 2021, 13, 656. [Google Scholar] [CrossRef]
  19. Tigas, S.; Tsatsoulis, A. Endocrine and metabolic manifestations in inflammatory bowel disease. Ann. Gastroenterol. 2012, 25, 37–44. [Google Scholar]
  20. Braun, T.P.; Marks, D.L. The regulation of muscle mass by endogenous glucocorticoids. Front. Physiol. 2015, 6, 12. [Google Scholar] [CrossRef]
  21. Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 2014, 14, 329–342. [Google Scholar] [CrossRef]
  22. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; Altman, D.; Antes, G.; Atkins, D.; Barbour, V.; Barrowman, N.; Berlin, J.A.; et al. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef] [PubMed]
  23. Boparai, G.; Kedia, S.; Kandasamy, D.; Sharma, R.; Madhusudhan, K.S.; Dash, N.R.; Sahu, P.; Pal, S.; Sahni, P.; Panwar, R.; et al. Combination of sarcopenia and high visceral fat predict poor outcomes in patients with Crohn’s disease. Eur. J. Clin. Nutr. 2021. [Google Scholar] [CrossRef]
  24. Celentano, V.; Kamil-Mustafa, L.; Beable, R.; Ball, C.; Flashman, K.G.; Jennings, Z.; O’Leary, D.P.; Higginson, A.; Luxton, S. Preoperative assessment of skeletal muscle mass during magnetic resonance enterography in patients with Crohn’s disease. Updates Surg. 2020. [Google Scholar] [CrossRef] [PubMed]
  25. Lee, C.H.; Yoon, H.; Oh, D.J.; Lee, J.M.; Choi, Y.J.; Shin, C.M.; Park, Y.S.; Kim, N.; Lee, D.H.; Kim, J.S. The prevalence of sarcopenia and its effect on prognosis in patients with Crohn’s disease. Intest. Res. 2020, 18, 79–84. [Google Scholar] [CrossRef]
  26. Thiberge, C.; Charpentier, C.; Gillibert, A.; Modzelewski, R.; Dacher, J.N.; Savoye, G.; Savoye-Collet, C. Lower subcutaneous or visceral adiposity assessed by abdominal computed tomography could predict adverse outcome in patients with Crohn’s disease. J. Crohns Colitis 2018, 12, 1429–1437. [Google Scholar] [CrossRef]
  27. Zhang, T.; Ding, C.; Xie, T.; Yang, J.; Dai, X.; Lv, T.; Li, Y.; Gu, L.; Wei, Y.; Gong, J.; et al. Skeletal muscle depletion correlates with disease activity in ulcerative colitis and is reversed after colectomy. Clin. Nutr. 2017, 36, 1586–1592. [Google Scholar] [CrossRef]
  28. Csontos, Á.A.; Molnár, A.; Piri, Z.; Pálfi, E.; Miheller, P. Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease. Rev. Esp. Enfermedades Dig. 2017, 109, 26–32. [Google Scholar] [CrossRef][Green Version]
  29. Holt, D.Q.; Moore, G.T.; Strauss, B.J.G.; Hamilton, A.L.; De Cruz, P.; Kamm, M.A. Visceral adiposity predicts post-operative Crohn’s disease recurrence. Aliment. Pharmacol. Ther. 2017, 45, 1255–1264. [Google Scholar] [CrossRef]
  30. Bamba, S.; Sasaki, M.; Takaoka, A.; Takahashi, K.; Imaeda, H.; Nishida, A.; Inatomi, O.; Sugimoto, M.; Andoh, A. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn’s disease. PLoS ONE 2017, 12, e0180036. [Google Scholar] [CrossRef]
  31. Cravo, M.L.; Velho, S.; Torres, J.; Costa Santos, M.P.; Palmela, C.; Cruz, R.; Strecht, J.; Maio, R.; Baracos, V. Lower skeletal muscle attenuation and high visceral fat index are associated with complicated disease in patients with Crohn’s disease: An exploratory study. Clin. Nutr. ESPEN 2017, 21, 79–85. [Google Scholar] [CrossRef]
  32. Bryant, R.V.; Ooi, S.; Schultz, C.G.; Goess, C.; Grafton, R.; Hughes, J.; Lim, A.; Bartholomeusz, F.D.; Andrews, J.M. Low muscle mass and sarcopenia: Common and predictive of osteopenia in inflammatory bowel disease. Aliment. Pharmacol. Ther. 2015, 41, 895–906. [Google Scholar] [CrossRef] [PubMed]
  33. Zhang, T.; Cao, L.; Cao, T.; Yang, J.; Gong, J.; Zhu, W.; Li, N.; Li, J. Prevalence of Sarcopenia and Its Impact on Postoperative Outcome in Patients with Crohn’s Disease Undergoing Bowel Resection. J. Parenter. Enter. Nutr. 2017, 41, 592–600. [Google Scholar] [CrossRef]
  34. Schneider, S.; Al-Jaouni, R.; Filippi, J.; Wiroth, J.B.; Zeanandin, G.; Arab, K.; Hébuterne, X. Sarcopenia is prevalent in patients with Crohn’s disease in clinical remission. Inflamm. Bowel Dis. 2008, 14, 1562–1568. [Google Scholar] [CrossRef]
  35. Lichtenstein, G.R.; Loftus, E.V.; Isaacs, K.L.; Regueiro, M.D.; Gerson, L.B.; Sands, B.E. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am. J. Gastroenterol. 2018, 113, 481–517. [Google Scholar] [CrossRef]
  36. Holick, M.F.; Binkley, N.C.; Bischoff-Ferrari, H.A.; Gordon, C.M.; Hanley, D.A.; Heaney, R.P.; Murad, M.H.; Weaver, C.M. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911–1930. [Google Scholar] [CrossRef]
  37. Pludowski, P.; Holick, M.F.; Grant, W.B.; Konstantynowicz, J.; Mascarenhas, M.R.; Haq, A.; Povoroznyuk, V.; Balatska, N.; Barbosa, A.P.; Karonova, T.; et al. Vitamin D supplementation guidelines. J. Steroid Biochem. Mol. Biol. 2018, 175, 125–135. [Google Scholar] [CrossRef]
  38. Munns, C.F.; Shaw, N.; Kiely, M.; Specker, B.L.; Thacher, T.D.; Ozono, K.; Michigami, T.; Tiosano, D.; Mughal, M.Z.; Mäkitie, O.; et al. Global consensus recommendations on prevention and management of nutritional rickets. J. Clin. Endocrinol. Metab. 2016, 101, 394–415. [Google Scholar] [CrossRef]
  39. MF, H. Vitamina D deficiency. N. Engl. J. Med. 2007, 357, 266–281. [Google Scholar]
  40. Janssen, C.E.; Globig, A.M.; Grawitz, A.B.; Bettinger, D.; Hasselblatt, P. Seasonal variability of vitamin D status in patients with inflammatory bowel disease—A retrospective cohort study. PLoS ONE 2019, 14, e0217238. [Google Scholar] [CrossRef] [PubMed]
  41. Burrelli Scotti, G.; Afferri, M.T.; De Carolis, A.; Vaiarello, V.; Fassino, V.; Ferrone, F.; Minisola, S.; Nieddu, L.; Vernia, P. Factors affecting vitamin D deficiency in active inflammatory bowel diseases. Dig. Liver Dis. 2019, 51, 657–662. [Google Scholar] [CrossRef]
  42. Mentella, M.C.; Scaldaferri, F.; Pizzoferrato, M.; Gasbarrini, A.; Miggiano, G.A.D. The association of disease activity, BMI and phase angle with vitamin D deficiency in patients with IBD. Nutrients 2019, 11, 2583. [Google Scholar] [CrossRef]
  43. Frigstad, S.O.; Høivik, M.L.; Jahnsen, J.; Cvancarova, M.; Grimstad, T.; Berset, I.P.; Huppertz-Hauss, G.; Hovde, Ø.; Bernklev, T.; Moum, B.; et al. Fatigue is not associated with Vitamin D deficiency in inflammatory bowel disease patients. World J. Gastroenterol. 2018, 24, 3293–3301. [Google Scholar] [CrossRef]
  44. Torella, M.C.; Rausch, A.; Lasa, J.; Zubiaurre, I. Vitamin D deficiency among inflammatory bowel disease patients in Argentina: A cross-sectional study. Arq. Gastroenterol. 2018, 55, 216–220. [Google Scholar] [CrossRef]
  45. Lin, S.; Wang, Y.; Li, L.; Chen, P.; Mao, R.; Feng, R.; Qiu, Y.; He, Y.; Chen, B.; Zeng, Z.; et al. A new model based on 25-hydroxyvitamin D3 for predicting active Crohn’s disease in Chinese patients. Mediat. Inflamm. 2018, 2018, 3275025. [Google Scholar] [CrossRef]
  46. Alrefai, D.; Jones, J.; El-Matary, W.; Whiting, S.J.; Aljebreen, A.; Mirhosseini, N.; Vatanparast, H. The association of vitamin D status with disease activity in a cohort of crohn′s disease patients in Canada. Nutrients 2017, 9, 1112. [Google Scholar] [CrossRef]
  47. Venkata, K.V.R.; Arora, S.S.; Xie, F.L.; Malik, T.A. Impact of Vitamin D on the hospitalization rate of Crohn’s disease patients seen at a tertiary care center. World J. Gastroenterol. 2017, 23, 2539–2544. [Google Scholar] [CrossRef]
  48. Pallav, K.; Riche, D.; May, W.L.; Sanchez, P.; Gupta, N.K. Predictors of Vitamin D deficiency in inflammatory bowel disease and health: A Mississippi perspective Retrospective Study. World J. Gastroenterol. 2017, 23, 638–645. [Google Scholar] [CrossRef] [PubMed]
  49. Da Silva Kotze, L.M.; Costa, C.T.; Cavassani, M.F.; Nisihara, R.M. Alert for bone alterations and low serum concentrations of Vitamin D in patients with intestinal in?ammatory disease. Rev. Assoc. Med. Bras. 2017, 63, 13–17. [Google Scholar] [CrossRef]
  50. Reich, K.M.; Fedorak, R.N.; Madsen, K.; Kroeker, K.I. Role of Vitamin D in Infliximab-induced Remission in Adult Patients with Crohn’s Disease. Inflamm. Bowel Dis. 2016, 22, 92–99. [Google Scholar] [CrossRef] [PubMed]
  51. Rebouças, P.C.; Netinho, J.G.; Cunrath, G.S.; Ronchi, L.S.; de Melo, M.M.C.; Gonçalves Filho, F.; Gonçalves Filho, F.d.A.; Muniz, R.C.C.; Martins, A.T.S.; de Oliveira, R.A.; et al. Association between vitamin D serum levels and disease activity markers in patients with Crohn’s Disease. Int. J. Colorectal Dis. 2016, 31, 1495–1496. [Google Scholar] [CrossRef]
  52. Xia, S.L.; Lin, X.X.; Guo, M.D.; Zhang, D.G.; Zheng, S.Z.; Jiang, L.J.; Jin, J.; Lin, X.Q.; Ding, R.; Jiang, Y. Association of vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D levels with Crohn’s disease in Chinese patients. J. Gastroenterol. Hepatol. 2016, 31, 795–801. [Google Scholar] [CrossRef]
  53. Dias de Castro, F.; Magalhães, J.; Boal Carvalho, P.; Moreira, M.J.; Mota, P.; Cotter, J. Lower levels of vitamin D correlate with clinical disease activity and quality of life in inflammatory bowel disease. Arq. Gastroenterol. 2015, 52, 260–265. [Google Scholar] [CrossRef]
  54. Raftery, T.; Merrick, M.; Healy, M.; Mahmud, N.; O’Morain, C.; Smith, S.; McNamara, D.; O’Sullivan, M. Vitamin D Status Is Associated with Intestinal Inflammation as Measured by Fecal Calprotectin in Crohn’s Disease in Clinical Remission. Dig. Dis. Sci. 2015, 60, 2427–2435. [Google Scholar] [CrossRef]
  55. De Bruyn, J.R.; van Heeckeren, R.; Ponsioen, C.Y.; van den Brink, G.R.; Löwenberg, M.; Bredenoord, A.J.; Frijstein, G.; D’Haens, G.R. Vitamin D deficiency in Crohn’s disease and healthy controls: A prospective case-control study in the Netherlands. J. Crohns Colitis 2014, 8, 1267–1273. [Google Scholar] [CrossRef] [PubMed]
  56. Dumitrescu, G.; Mihai, C.; Dranga, M.; Prelipcean, C.C. Serum 25-hydroxyvitamin D concentration and inflammatory bowel disease characteristics in Romania. World J. Gastroenterol. 2014, 20, 2392–2396. [Google Scholar] [CrossRef] [PubMed]
  57. Hlavaty, T.; Krajcovicova, A.; Koller, T.; Toth, J.; Nevidanska, M.; Huorka, M.; Payer, J. Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases. World J. Gastroenterol. 2014, 20, 15787–15796. [Google Scholar] [CrossRef]
  58. Veit, L.E.; Maranda, L.; Fong, J.; Nwosu, B.U. The vitamin D status in inflammatory bowel disease. PLoS ONE 2014, 9, e101583. [Google Scholar] [CrossRef] [PubMed]
  59. Salacinski, A.J.; Regueiro, M.D.; Broeder, C.E.; McCrory, J.L. Decreased neuromuscular function in Crohn’s disease patients is not associated with low serum vitamin D levels. Dig. Dis. Sci. 2013, 58, 526–533. [Google Scholar] [CrossRef]
  60. Fu, Y.T.N.; Chatur, N.; Cheong-Lee, C.; Salh, B. Hypovitaminosis D in adults with inflammatory bowel disease: Potential role of ethnicity. Dig. Dis. Sci. 2012, 57, 2144–2148. [Google Scholar] [CrossRef]
  61. Nic Suibhne, T.; Cox, G.; Healy, M.; O’Morain, C.; O’Sullivan, M. Vitamin D deficiency in Crohn’s disease: Prevalence, risk factors and supplement use in an outpatient setting. J. Crohns Colitis 2012, 6, 182–188. [Google Scholar] [CrossRef] [PubMed]
  62. Atia, A.; Murthy, R.; Bailey, B.A.; Manning, T.; Garrett, L.L.; Youssef, D.; Peiris, A.N. Vitamin D Status in Veterans with inflammatory bowel disease: Relationship to Health care costs and services. Mil. Med. 2011, 176, 711–714. [Google Scholar] [CrossRef] [PubMed][Green Version]
  63. Jørgensen, S.P.; Agnholt, J.; Glerup, H.; Lyhne, S.; Villadsen, G.E.; Hvas, C.L.; Bartels, L.E.; Kelsen, J.; Christensen, L.A.; Dahlerup, J.F. Clinical trial: Vitamin D3 treatment in Crohn’s disease—A randomized double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 2010, 32, 377–383. [Google Scholar] [CrossRef] [PubMed]
  64. Kuwabara, A.; Tanaka, K.; Tsugawa, N.; Nakase, H.; Tsuji, H.; Shide, K.; Kamao, M.; Chiba, T.; Inagaki, N.; Okano, T.; et al. High prevalence of vitamin K and D deficiency and decreased BMD in inflammatory bowel disease. Osteoporos. Int. 2009, 20, 935–942. [Google Scholar] [CrossRef] [PubMed]
  65. Gilman, J.; Shanahan, F.; Cashman, K.D. Determinants of vitamin D status in adult Crohn’s disease patients, with particular emphasis on supplemental vitamin D use. Eur. J. Clin. Nutr. 2006, 60, 889–896. [Google Scholar] [CrossRef]
  66. McCarthy, D.; Duggan, P.; O’Brien, M.; Kiely, M.; McCarthy, J.; Shanahan, F.; Cashman, K.D. Seasonality of vitamin D status and bone turnover in patients with Crohn’s disease. Aliment. Pharmacol. Ther. 2005, 21, 1073–1083. [Google Scholar] [CrossRef]
  67. Tajika, M.; Matsuura, A.; Nakamura, T.; Suzuki, T.; Sawaki, A.; Kato, T.; Hara, K.; Ookubo, K.; Yamo, K.; Kato, M.; et al. Risk factors for vitamin D deficiency in patients with Crohn’s disease. J. Gastroenterol. 2004, 39, 527–533. [Google Scholar] [CrossRef]
  68. Siffledeen, J.S.; Siminoski, K.; Steinhart, H.; Greenberg, G.; Fedorak, R.N. The frequency of vitamin D deficiency in adults with Crohn’s disease. Can. J. Gastroenterol. 2003, 17, 473–478. [Google Scholar] [CrossRef]
  69. Jahnsen, J.; Falch, J.A.; Mowinckel, P.; Aadland, E. Vitamin D status, parathyroid hormone and bone mineral density in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 2002, 37, 192–199. [Google Scholar] [CrossRef]
  70. Xie, Z.; Wang, X.; Bikle, D.D. Editorial: Vitamin D Binding Protein, Total and Free Vitamin D Levels in Different Physiological and Pathophysiological Conditions. Front. Endocrinol. 2020, 11, 317. [Google Scholar] [CrossRef]
  71. Agergaard, J.; Trøstrup, J.; Uth, J.; Iversen, J.V.; Boesen, A.; Andersen, J.L.; Schjerling, P.; Langberg, H. Does vitamin-D intake during resistance training improve the skeletal muscle hypertrophic and strength response in young and elderly men?—A randomized controlled trial. Nutr. Metab. 2015, 12, 32. [Google Scholar] [CrossRef] [PubMed]
  72. Garcia, L.A.; King, K.K.; Ferrini, M.G.; Norris, K.C.; Artaza, J.N. 1,25(OH)2 vitamin D3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 2011, 152, 2976–2986. [Google Scholar] [CrossRef] [PubMed]
  73. Angeline, M.E.; Gee, A.O.; Shindle, M.; Warren, R.F.; Rodeo, S.A. The effects of vitamin d deficiency in athletes. Am. J. Sports Med. 2013, 41, 461–464. [Google Scholar] [CrossRef] [PubMed]
  74. Remelli, F.; Vitali, A.; Zurlo, A.; Volpato, S. Vitamin D deficiency and sarcopenia in older persons. Nutrients 2019, 11, 2861. [Google Scholar] [CrossRef] [PubMed]
  75. Pojednic, R.M.; Ceglia, L. The emerging biomolecular role of vitamin D in skeletal muscle. Exerc. Sport Sci. Rev. 2014, 42, 76–81. [Google Scholar] [CrossRef] [PubMed]
  76. Knutsen, K.V.; Brekke, M.; Gjelstad, S.; Lagerløv, P. Vitamin D status in patients with musculoskeletal pain, fatigue and headache: A cross-sectional descriptive study in a multi-ethnic general practice in Norway. Scand. J. Prim. Health Care 2010, 28, 166–171. [Google Scholar] [CrossRef]
  77. Visser, M.; Deeg, D.J.H.; Lips, P. Low Vitamin D and High Parathyroid Hormone Levels as Determinants of Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging Study Amsterdam. J. Clin. Endocrinol. Metab. 2003, 88, 5766–5772. [Google Scholar] [CrossRef]
  78. Boettger, S.F.; Angersbach, B.; Klimek, C.N.; Wanderley, A.L.M.; Shaibekov, A.; Sieske, L.; Wang, B.; Zuchowski, M.; Wirth, R.; Pourhassan, M. Prevalence and predictors of vitamin D-deficiency in frail older hospitalized patients. BMC Geriatr. 2018, 18, 219. [Google Scholar] [CrossRef]
  79. Granic, A.; Hil, T.R.; Davies, K.; Jagger, C.; Adamson, A.; Siervo, M.; Kirkwood, T.B.L.; Mathers, J.C.; Sayer, A.A. Vitamin d status, muscle strength and physical performance decline in very old adults: A prospective study. Nutrients 2017, 9, 379. [Google Scholar] [CrossRef]
  80. Bischoff-Ferrari, H.A.; Borchers, M.; Gudat, F.; Dürmüller, U.; Stähelin, H.B.; Dick, W. Vitamin D Receptor Expression in Human Muscle Tissue Decreases with Age. J. Bone Miner. Res. 2004, 19, 265–269. [Google Scholar] [CrossRef]
  81. Hill, T.R.; Aspray, T.J.; Francis, R.M. Vitamin D and bone health outcomes in older age. In Proceedings of the Nutrition Society; Cambridge University Press: Cambridge, UK, 2013; Volume 72, pp. 372–380. [Google Scholar]
  82. Rigterink, T.; Appleton, L.; Day, A.S. Vitamin D therapy in children with inflammatory bowel disease: A systematic review. World J. Clin. Pediatr. 2019, 8, 1–14. [Google Scholar] [CrossRef] [PubMed]
  83. Hradsky, O.; Soucek, O.; Maratova, K.; Matyskova, J.; Copova, I.; Zarubova, K.; Bronsky, J.; Sumnik, Z. Supplementation with 2000 IU of Cholecalciferol is Associated with Improvement of Trabecular Bone Mineral Density and Muscle Power in Pediatric Patients with IBD. Inflamm. Bowel Dis. 2017, 23, 514–523. [Google Scholar] [CrossRef] [PubMed]
Nutrients 13 01378 g001
Figure 1. Different mechanisms are involved in the pathogenesis of sarcopenia in patients with CD. The combined effect of inflammatory cytokines (e.g., TNF-α, IL-6) in determining increased muscle protein degradation, through NF-KB and increased Myostatin activity, are here summarized. By reducing IGF-1 and its related intracellular signal pathway, along with the decreased amino acid absorption also due to therapeutic interventions, chronic inflammation determines a diminished protein synthesis. Abbreviations: TNF-α: tumor necrosis factor Alfa; IL-6: interleukin 6; PI3K: phosphatidylinositol-3-kinase; AKT: protein kinase B; mTORC1: mammalian target of rapamycin complex; IGF-1: Insulin-Like Growth Factor-1; NF-KB: Nuclear Factor Kappa B.
Figure 1. Different mechanisms are involved in the pathogenesis of sarcopenia in patients with CD. The combined effect of inflammatory cytokines (e.g., TNF-α, IL-6) in determining increased muscle protein degradation, through NF-KB and increased Myostatin activity, are here summarized. By reducing IGF-1 and its related intracellular signal pathway, along with the decreased amino acid absorption also due to therapeutic interventions, chronic inflammation determines a diminished protein synthesis. Abbreviations: TNF-α: tumor necrosis factor Alfa; IL-6: interleukin 6; PI3K: phosphatidylinositol-3-kinase; AKT: protein kinase B; mTORC1: mammalian target of rapamycin complex; IGF-1: Insulin-Like Growth Factor-1; NF-KB: Nuclear Factor Kappa B.
Nutrients 13 01378 g001
Nutrients 13 01378 g002
Figure 2. Flow diagram of the study selection process (adapted from PRISMA) [22].
Figure 2. Flow diagram of the study selection process (adapted from PRISMA) [22].
Nutrients 13 01378 g002
Nutrients 13 01378 g003
Figure 3. Flow diagram of the study selection process (adapted from PRISMA) [22].
Figure 3. Flow diagram of the study selection process (adapted from PRISMA) [22].
Nutrients 13 01378 g003
Nutrients 13 01378 g004
Figure 4. Brief overview of the genomic and non-genomic pathways of vitamin D at muscle cellular level. Vitamin D regulates gene expression in the nucleus by interacting with VDR, thus forming a heterodimeric complex of liganded VDR with RXR and upregulating or downregulating target genes transcription. The non-genomic effects of Vitamin D are mediated by the activation of several intracellular signal pathways through signal molecules, e.g., phospholipase C and phospholipase A2, and the production of second messengers, protein kinases, and the opening of Ca2+ and Cl− channels. Abbreviations: VDR: Vitamin D Receptor; RXR: Retinoid-X-receptor; 1,25VitD: 1,25-hydroxyvitamin D.
Figure 4. Brief overview of the genomic and non-genomic pathways of vitamin D at muscle cellular level. Vitamin D regulates gene expression in the nucleus by interacting with VDR, thus forming a heterodimeric complex of liganded VDR with RXR and upregulating or downregulating target genes transcription. The non-genomic effects of Vitamin D are mediated by the activation of several intracellular signal pathways through signal molecules, e.g., phospholipase C and phospholipase A2, and the production of second messengers, protein kinases, and the opening of Ca2+ and Cl− channels. Abbreviations: VDR: Vitamin D Receptor; RXR: Retinoid-X-receptor; 1,25VitD: 1,25-hydroxyvitamin D.
Nutrients 13 01378 g004
Table 1. Validated tests for the assessment of muscle strength and muscle quantity.
Table 1. Validated tests for the assessment of muscle strength and muscle quantity.
VariableParameterTestToolAdvantagesDisadvantages
Skeletal Muscle StrengthGSGSTDynamometerSimple and inexpensive.
  • Provides only an approximation for the strength of arm muscles.
  • Not possible to perform in case of hands disability.
CSTNoneSimple and inexpensive.
  • Provides only an approximation for the strength of leg muscles.
  • Not possible to perform in case of leg disability.
Skeletal Muscle QuantitySMMASMIBIA; DXA
  • Detailed information on the body composition
  • Relatively low-cost method.
  • Short time required.
  • Requires trained physicians
  • Use of ionizing radiations (DXA)
SMMMCSACT; MRIThe gold-standard methods.
  • Requires highly trained personnel.
  • Expensive tests.
  • Time-consuming.
  • Use of ionizing radiations (CT).
  • Cut-off points for low muscle mass are not yet well defined.
Abbreviations: GS: grip strength; GST: grip strength test; CST: chair stand test; ASMI: appendicular skeletal muscle index; SMM: skeletal muscle mass; BIA: bioelectrical impedance analysis; DXA: Dual-energy X-ray absorptiometry; CT: computed tomography; MRI: magnetic resonance imaging; MCSA: muscle cross-sectional area.
Table 2. Prevalence of Sarcopenia in Crohn’s Disease (CD).
Table 2. Prevalence of Sarcopenia in Crohn’s Disease (CD).
AuthorsYearnAge
(Years)		VariableTestToolSarcopenia
(%)
Boparai [23]20214434 ± 14.1 *SMQMCSACT43
Celentano et al. [24]20203146 (49–72) †SMQMCSAMRI38
Lee et al. [25]20207929 ± 11.3 *SMQMCSACT50
Grillot et al. [3]20208835 ± 12.4 *SMQMCSACT58
Thiberge et al. [26]201814941 ± 17.5 *SMQMCSACT33.6
Zhang T. et al. [27]2017105−SMQMCSACT59
Csontos et al. [28]201712634 ± 11.5 *SMQASMIBIA29.4
Holt et al. [29]20174438 ± 14.2 *SMQMCSACT
MRI		41
Bamba et al. [30]20174329 (25–37) †SMQMCSACT37
Cravo et al. [31]20177143SMQMCSACT31
Bryant et al. [32]20159531 (27–39) †SMQ
SMS		ASMI
GST		BIA
Dyn		19
27
Zhang T. et al. [33]201511432 ± 11.5 *SMQMCSACT61.4
Schneider et al. [34]20088236 ± 13.9 *SMQASMIDXA60
Abbreviations: SMS: skeletal muscle strength; SMQ: skeletal muscle quantity; ASMI: appendicular skeletal muscle index; MCSA: muscle cross-sectional area; GST: grip strength test; Dyn: dynamometer; MRI: magnetic resonance imaging; CT: computed tomography; BIA: bioelectrical impedance analysis; DXA: Dual-energy X-ray absorptiometry; yr: year; − not found in the article; * the mean ± standard deviation; † the median range.
Table 3. Prevalence of Vitamin D deficiency in Crohn’s Disease (CD).
Table 3. Prevalence of Vitamin D deficiency in Crohn’s Disease (CD).
AuthorsYearnAge
(Years)		25(OH)D Cut-Off
(ng/mL)		Vitamin D Deficiency
(%)
Janssen et al. [40]201925643 (18–85) †<20
20–30		63%
24%
Burrelli Scotti et al. [41]201933
78		-<2039.6% 1
50% 2
Mentella et al. [42]201910137.9 ± 16.64 *<20
<30		38.6%
25.7%
Frigstad et al. [43]201822740 (18–77) †<2055%
Torella et al. [44]201814-<3078.6%
Lin et al. [45]2018346-<2082.7%
Alrefai et al. [46]201720140 ± 15.2 *<12
12–20		18%
26%
Venkata et al. [47]2017196−<3058.7%
Pallav et al. [48]2017129−<2040.3%
da Silva Kotze et al. [49]20173840 (16–73) †<20
20–30		10.5%
65.8%
Reich et al. [50]201628−<3053.6%
Rebouças et al. [51]20167541 ± 15.6 *<3062.7%
Xia et al. [52]201612427.6 ± 8.6 *<2067.8%
De Castro et al. [53]20155733 ± 9.8 *<20
<30		33%
72%
Raftery et al. [54]201511945 ± 11.8 *<2036.1%
de Bruyn et al. [55]201410141 (30–50) †<2054%
Dumitrescu et al. [56]20141436 ± 9 *<20
<30		36%
43%
Hlavaty et al. [57]2014124
97		-
-		<1260% 1
74% 2
Veit et al. [58]20144016.6 ± 2.2 *<2040%
Salacinski et al. [59]20131944 ± 10.3 *<20
20–30		10.5%
37%
Fu et al. [60]20124040 ± 13.2 *<2042.5%
Suibhne et al. [61]20128136 ± 11 *<2063%
Atia et al. [62]20114361 ± 14.7 *<20
<30		51.2%
83.7%
Jørgensen et al. [63]201094-<2030.9%
Kuwabara et al. [64]20092932 ± 6.7 *<20100%
Gilman et al. [65]20065838 ± 10.9 *<2019% 1
50% 2
McCarthy et al. [66]20054437 ± 11.1 *<2018.2% 1
50% 2
Tajika et al. [67]20043338 ± 7.5 *≤1027.3%
Siffledeen et al. [68]2003242-<10
<16		8%
22%
Jahnsen et al. [69]200260-<1227%
Abbreviations: yr: year; 25(OH)D: 25-hydroxyvitamin D; 1: percentage in summer; 2: percentage in winter; − not found in the article; * the mean ± standard deviation. † the median range.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Palmese, F.; Del Toro, R.; Di Marzio, G.; Cataleta, P.; Sama, M.G.; Domenicali, M. Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together. Nutrients 2021, 13, 1378. https://doi.org/10.3390/nu13041378

AMA Style

Palmese F, Del Toro R, Di Marzio G, Cataleta P, Sama MG, Domenicali M. Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together. Nutrients. 2021; 13(4):1378. https://doi.org/10.3390/nu13041378

Chicago/Turabian Style

Palmese, Francesco, Rossella Del Toro, Giulia Di Marzio, Pierluigi Cataleta, Maria Giulia Sama, and Marco Domenicali. 2021. "Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together" Nutrients 13, no. 4: 1378. https://doi.org/10.3390/nu13041378

APA Style

Palmese, F., Del Toro, R., Di Marzio, G., Cataleta, P., Sama, M. G., & Domenicali, M. (2021). Sarcopenia and Vitamin D Deficiency in Patients with Crohn’s Disease: Pathological Conditions That Should Be Linked Together. Nutrients, 13(4), 1378. https://doi.org/10.3390/nu13041378

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop